

10/583877

"Express Mail Certificate AP3 Rec'd PCT/PTO 21 JUN 2006
Express Mail Mailing Label Number EV 710806197 US
Date of Deposit: 21 June 2006

Attorney Docket No.: PB60608

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ellis, et al.
Serial No.: To be Assigned Group Art Unit No.: Unknown
Filed: Herewith Examiner: Unknown
For: NOGO-A NEUTRALISING IMMUNOGLOBULINS FOR TREATMENT OF
NEUROLOGICAL DISEASES

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

Commissioner for Patents
Mail Stop: Sequence
P.O. Box 1450
Alexandria, Va 22313-1450

(X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

(X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (g) does not include new matter.

() I hereby state that the submission filed in accordance with 37 CFR §1.821 (h) does not include new matter or go beyond the disclosure in the international application as filed.

() I hereby state that the amendments, made in accordance with 37 CFR §1.825 (a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,



Elizabeth J. Hecht
Attorney for Applicants
Registration No. 41,824

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5009
Facsimile (610) 270-5090
N:\EJH\APPLNSP Cases_\PB\PB60608\US National Sequence Listing Transmittal.doc